By Suherman Candra Maholtra 
The global healthcare landscape underwent a seismic shift on December 8, 2020, when the first clinically tested messenger RNA (mRNA) vaccine for COVID-19 was administered to the public. This milestone marked the culmination of decades of research into nucleic acid therapeutics, providing a rapid-response tool that, according to mathematical modeling from Imperial College London and other institutions, prevented an estimated 14.4 million deaths in its first year of rollout alone. However, as the world moves beyond the acute phase of the pandemic, the limitations of mRNA technology—ranging from logistical hurdles to waning immunity—have prompted a search for the next generation of vaccine platforms. A multidisciplinary team led by the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute (DFCI) has recently unveiled a sophisticated alternative: a DNA origami-based platform known as DoriVac. This nanotechnology, detailed in a recent publication in Nature Biomedical Engineering, offers a programmable, stable, and highly potent method for eliciting immune responses against viruses such as SARS-CoV-2, HIV, and Ebola.
The Evolution of Vaccine Technology: From mRNA Success to Modern Limitations
The success of mRNA vaccines during the COVID-19 pandemic demonstrated the power of using genetic instructions to prompt human cells to produce viral antigens. By bypassing the need to grow weakened or inactivated viruses in eggs or bioreactors, mRNA technology allowed for unprecedented development speed. Yet, the long-term application of mRNA has revealed significant challenges. Firstly, the immunity conferred by current mRNA-lipid nanoparticle (LNP) formulations tends to diminish over several months, necessitating frequent booster shots. Secondly, the rapid mutation of the SARS-CoV-2 virus, particularly in the spike protein’s receptor-binding domain, has allowed new variants to partially evade the antibodies generated by original vaccine strains.
Beyond biological limitations, the physical requirements of mRNA vaccines create a "cold-chain" crisis for global health equity. Because mRNA is inherently unstable and LNPs are delicate, these vaccines often require ultra-low temperature storage (between -60°C and -90°C), making distribution nearly impossible in rural or under-resourced regions of the Global South. Furthermore, the manufacturing process for LNPs is notoriously difficult to scale with precision; controlling the exact number of mRNA molecules per nanoparticle remains a hurdle in quality control. These factors have driven researchers to investigate DNA origami—a method of folding DNA into specific 3D shapes—as a more robust "chassis" for vaccine delivery.
Chronology of the DoriVac Development
The journey toward the DoriVac platform began well before the COVID-19 pandemic. For years, William Shih, Ph.D., a Core Faculty member at the Wyss Institute and Professor at Harvard Medical School, pioneered the field of DNA origami. His work focused on using the predictable base-pairing of DNA to create self-assembling nanostructures with atomic-level precision.
By 2023, Yang (Claire) Zeng, M.D., Ph.D., and her colleagues had successfully demonstrated that these DNA nanostructures could serve as effective carriers for cancer immunotherapy. In early trials involving tumor-bearing mice, DoriVac proved capable of delivering adjuvants—molecules that jumpstart the immune system—directly to dendritic cells, leading to significant tumor regression. However, as the pandemic persisted, the team pivoted their focus. In 2024, they expanded the platform to address infectious diseases, seeking to determine if the same precision used to target cancer cells could be used to neutralize highly mutable viruses.
Through a collaboration between the Shih lab, the Dana-Farber Cancer Institute, and Donald Ingber’s team at the Wyss Institute, the researchers integrated advanced AI-driven modeling and "Organ-on-a-Chip" technology to refine the DoriVac platform. This collaborative effort culminated in the recent study comparing DoriVac directly against the industry-standard mRNA-LNP vaccines produced by Pfizer/BioNTech and Moderna.
The Architecture of a DNA Origami Vaccine
The DoriVac platform is built upon a self-assembling DNA "nanosquare." This structure is not merely a passive carrier; it is a programmable scaffold. One side of the square is engineered to display adjuvant molecules—specifically CpG oligonucleotides—at precise nanometer intervals. Research has shown that the spacing of these molecules is critical; if they are positioned too close or too far apart, the immune system’s receptors (such as TLR9) are not activated as efficiently.
On the opposite side of the DNA scaffold, the researchers attach specific viral antigens. In their latest study, the team focused on the HR2 (heptad repeat 2) peptide. Unlike the receptor-binding domain of the spike protein, which mutates frequently, the HR2 region is highly conserved across various strains of SARS-CoV-2 and even across different viruses like HIV and Ebola. By targeting this "fusion engine" of the virus, the DoriVac platform aims to provide broader, "variant-proof" protection.
"With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages," stated William Shih. "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses."
Supporting Data: Head-to-Head Comparison with mRNA
To validate the efficacy of DoriVac, the research team conducted a series of rigorous comparisons. In mouse models, a DoriVac vaccine carrying the full SARS-CoV-2 spike protein was tested against the mRNA-LNP vaccines used globally. The results indicated that DoriVac produced a comparable level of neutralizing antibodies and T-cell responses.
Specific data points from the study highlighted several key advantages:
- Cellular Immunity: DoriVac significantly increased the population of memory T cells and cytotoxic "killer" T cells. These cells are essential for long-term protection and for clearing virus-infected cells that antibodies might miss.
- Adjuvant Efficiency: The DNA origami structure allowed for a "self-adjuvanted" effect. Because the adjuvants were presented in a highly organized nanostructure, the immune response was significantly stronger than when the same antigens and adjuvants were delivered as a loose mixture.
- Humoral Response: In tests involving the HR2 peptide, DoriVac triggered a robust production of B cells, the "factories" responsible for churning out antibodies.
Perhaps the most significant data emerged from the stability testing. Unlike mRNA, which degrades rapidly at room temperature, the DNA origami structures showed remarkable resilience. This suggests that DoriVac could potentially be stored in standard refrigeration or even in a lyophilized (freeze-dried) state, eliminating the need for the expensive and complex ultra-cold chain.
Utilizing Human Organ-on-a-Chip for Preclinical Validation
One of the most innovative aspects of this research was the use of the Wyss Institute’s "Human Lymph Node-on-a-Chip." This microfluidic device simulates the environment of a human lymph node, allowing researchers to observe how human immune cells react to a vaccine in real-time without the ethical and safety risks of early human trials.
Because mouse immune systems often fail to predict human outcomes—a phenomenon that has led to the failure of many promising vaccines in Phase I clinical trials—the "LN Chip" provided a crucial bridge. When the DoriVac vaccine was introduced to the chip, it successfully activated human dendritic cells and induced the production of inflammatory cytokines. Furthermore, it stimulated the proliferation of CD4+ and CD8+ T cells, providing a high-degree of confidence that the platform would be effective in human recipients.
Donald Ingber, M.D., Ph.D., Director of the Wyss Institute, emphasized the importance of this testing: "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines… This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines."
Official Responses and Strategic Implications
The emergence of DoriVac has been met with optimism from the scientific and biotechnology communities. Yang (Claire) Zeng, now the CEO and CTO of DoriNano, is leading the effort to translate this laboratory success into clinical reality. She noted that the platform’s ability to "program immune recognition" at a molecular level allows for a degree of control that was previously impossible with traditional vaccine methods.
Industry analysts suggest that if DoriVac successfully navigates clinical trials, it could disrupt the current dominance of mRNA. The ease of manufacturing is a primary factor; while LNPs require complex microfluidic mixing and specialized lipids, DNA origami relies on DNA strands that can be synthesized cheaply and in high volume.
Furthermore, the safety profile of DNA-based nanostructures is appearing favorable. While some mRNA recipients have reported transient side effects or rare instances of myocarditis, the DoriVac platform has shown a promising safety profile in early studies, likely due to its highly targeted nature which reduces "off-target" effects in the body.
Analysis of Broader Impact and Global Health
The implications of a stable, programmable DNA origami vaccine platform extend far beyond COVID-19. The world currently faces ongoing threats from tuberculosis, Zika, and the ever-present risk of an avian influenza jump to humans. For diseases like HIV, which have eluded vaccine developers for decades due to the virus’s rapid mutation, the DoriVac approach of targeting highly conserved regions like HR2 offers a new glimmer of hope.
From a geopolitical perspective, DoriVac could be the key to "vaccine sovereignty" for developing nations. By reducing the reliance on ultra-cold storage and simplifying the manufacturing process, countries with less developed infrastructure could produce and distribute their own vaccines, tailored to local variants and needs.
As the Wyss Institute and DoriNano move toward Phase I trials, the scientific community will be watching closely. The transition from mRNA—a technology that saved millions—to DNA origami represents a natural progression in the field of synthetic biology. If the results seen in the Human LN Chip translate to human patients, DoriVac may not only supplement the current vaccine arsenal but could become the gold standard for responding to the next "Disease X."
The study, supported by a vast array of institutions including the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, and the National Research Foundation of Korea, underscores the global consensus that the next generation of vaccines must be more stable, more accessible, and more precise than those of the past. With DoriVac, the blueprint for that future appears to be written in the very DNA it seeks to protect.
